Oncobiologics Inc.

Biotechnology ResearchNew Jersey, United States11-50 Employees

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, with a current emphasis on monoclonal antibodies in immunology and oncology. The organization pursues cost-effective development on an accelerated timeline and maintains an integrated in-house capability, known as the BioSymphony Platform, to address the technical and regulatory challenges of bringing mAb biosimilars to market and to support pricing flexibility. The company is based in Cranbury, New Jersey, and operates as a small to mid-sized biotechnology firm with a strategic emphasis on biosimilars.

The company maintains a portfolio of eight monoclonal antibody biosimilars, including its most advanced assets ONS-3010 (Humira biosimilar) and ONS-1045 (Avastin biosimilar), both of which have completed Phase I trials and for which Phase 3 preparatory activities have been initiated. In addition to its own development efforts, Oncobiologics offers contract development and manufacturing services to other development-stage biologics companies through its platform. The organization situates itself within the biotechnology research industry as a specialized biosimilars-focused firm.

Sign up for free to view info

Email Format Employee directory